First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area.
Carcinoma, Non-Small-Cell Lung
n/a - n/a
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Oct 2023 by AstraZeneca
No locations available
The PACIFIC-AA is designed to enroll stage III unresectable NSCLC patients who received durvalumab after completion of chemoradiation therapy within an early access program in Taiwan during 2018 to 2019.